4. CONCLUSIONS
Using the HAL9/10 libraries, we were able to select antibodies with high
affinity for KLK7, and they also showed a high capacity to inhibit the
proteolytic activity of this targeted enzyme. These recombinant
antibodies were incorporated in a drug delivery system that was
generated from poloxamers, and we demonstrated the viability of the
system to encapsulate and deliver the antibodies, showing satisfactory
pharmacological parameters for LUP-37A10 and LUP-37C11 in formulation F1
and LUP-37D11 in formulation F2. Our work has combined phage display and
drug delivery methodologies to generate new molecules and formulations
with potential for use in therapies for the pathologies in which KLK7
appears to be involved.